Momentum Source

[Momentum Source @MomentumSource]

👀 WHY WE ARE WATCHING $DGNX AT THE OPEN

• Fresh company catalyst
• Volume jumped to 1M+ shares yesterday
• $1.38 key support area
• $1.55–$1.58 first major resistance zone
• Major shareholder vote approaching on the proposed $1.05B Resulticks acquisition

Advertisement. See full disclosure. Full breakdown 👇
https://t.co/HrkpzeAabc

[Momentum Source @MomentumSource]

$DGNX 👀

October could be a BIG month.

📅 Oct. 8 shareholder vote
🤖 Proposed $1.05B combination with AI-powered Resulticks
📈 Resulticks reported $150M FY2025 revenue
🧠 Diginex expanding its sustainability + AI intelligence strategy

There’s a lot happening here — and the upcoming catalyst window is one to watch closely.

Full breakdown. Please see disclosure below 👇
https://t.co/HrkpzeAabc

#Stocks #AI #NASDAQ

[Bull Theory @BullTheoryio]

🚨 THIS IS NOT LOOKING GOOD.

Entire US bond yield curve is going parabolic.

US01Y is at a 25-month high

US02Y is at a 28-month high

US05Y is at a 19-year high

US10Y is at a 19-year high

US20Y is also at a 22-year high

US30Y is at a 19-year high

Higher yields across the board mean higher borrowing costs for the government, businesses, and consumers, and that's bad news for both the economy and stocks.

[Momentum Source @MomentumSource]

Trading isn’t about catching every move.

It’s about protecting your capital long enough to catch the RIGHT moves.

Small size.
Defined risk.
Add to confirmation.
Cut what isn’t working.
Press when you’re right.

Consistency first. Size is earned. 📈

[Momentum Source @MomentumSource]

🚨 TOMORROW — 9:00 AM ET 🚨

A drone company just added another major piece to its expansion story.

🛡️ Qualified supplier pathway for defense
🚁 29th Drone-as-a-Service acquisition completed
🌾 New aviation authorization
📈 Multiple potential routes to future growth

The ticker stays hidden until the countdown hits ZERO.

This is one you’ll want on your radar. 👀

Full report preview 👇
https://t.co/Zbx2acJgx8

[Momentum Source @MomentumSource]

🚨 $SBFM IS ON OUR RADAR THIS MORNING 🚨

Sunshine Biopharma just added another major development to the story:

🧬 Lead coronavirus antiviral advanced into IND-enabling studies
💊 60 generic prescription drugs now on the Canadian market
💰 $9.26M in Q2 revenue
��� $13.75M cash reported at June 30
📈 Recent rebound off the $0.82 area

Padvertisement. See full disclosure.
Full report 👇 https://t.co/VS1gZGWFmH

[Momentum Source @MomentumSource]

🚨 TOMORROW MORNING 🚨

We’ve been digging into a company with a lot happening beneath the surface…

💰 $9.26M in Q2 revenue
🧬 Antiviral program advancing into IND-enabling studies
💊 60 generic prescription drugs already on the Canadian market
📈 A recent technical rebound worth watching

⏰ Full ticker reveal: 9:30 AM ET

Read the report before the ticker drops 👇
https://t.co/b6fwx8hadf

Paid advertisement. See full disclosure.

[Momentum Source @MomentumSource]

$PHOS IS WAKING UP. 👀🔥

Up 10%+ on the day and already tagged $16.32.

The momentum is here. The chart is speaking for itself.

Now the question is… who’s paying attention?

👀 📈

[Momentum Source @MomentumSource]

🚨 $PHOS IS ON OUR RADAR 🚨

First Phosphate recently made its Nasdaq debut — and the numbers behind the story are worth a look. 👀

⛏️ 204.7M tonnes measured + indicated
📊 89.5M tonnes inferred
💰 $1.14B modeled after-tax NPV
🏛️ Government funding + offtake support
📈 Critical-minerals / LFP battery exposure

But this is still a development-stage story, and financing, feasibility + execution remain key.

PAID ADVERTISEMENT: See full disclosure.
https://t.co/BXRSCpYOhk

[Momentum Source @MomentumSource]

FED UNANIMOUSLY RAISES BENCHMARK RATE 25 BPS TO 3.75%-4% RANGE

[Momentum Source @MomentumSource]

🚨 $PHOS IS ON OUR RADAR 🚨

First Phosphate recently made its Nasdaq debut — and the numbers behind the story are worth a look. 👀

⛏️ 204.7M tonnes measured + indicated
📊 89.5M tonnes inferred
💰 $1.14B modeled after-tax NPV
🏛️ Government funding + offtake support
📈 Critical-minerals / LFP battery exposure

But this is still a development-stage story, and financing, feasibility + execution remain key.

PAID ADVERTISEMENT: See full disclosure.
https://t.co/BXRSCpYOhk

[Momentum Source @MomentumSource]

🚨 NEW ALERT DROPPING TODAY 🚨

⛏️ Massive North American resource
💰 $1B+ modeled after-tax NPV
🔋 Positioned around the LFP battery supply chain
🏛️ Government support
🤝 Strategic offtake agreements

And almost nobody is talking about it yet.

We’re dropping the full breakdown shortly.

Stay tuned. 👀

[Momentum Source @MomentumSource]

🚨 $MDCX x $PFE DEAL JUST HIT 🚨

Medicus Pharma has entered into a Co-Development & License Agreement with Pfizer for CD228V. 👀

🔥 Exclusive worldwide license under specified Pfizer patent rights
🧬 Pfizer expected to remain involved in the CD228V program
💰 Aggregate potential milestone payments exceed $1 BILLION
💵 Pfizer eligible for low double-digit royalties on net sales
🎯 Agreement covers potential development across multiple indications

See disclosure below 👇

[Momentum Source @MomentumSource]

🚨 $MDCX — THIS ONE HAS OUR ATTENTION 👀

Small-cap biotech. Multiple shots on goal. A valuation that’s hard to ignore.

🧬 FDA-authorized Phase 2b study
🎯 THREE clinical programs advancing
💰 ~$15M unrestricted cash reported
🔥 Market cap around just ~$16M
⏳ Multiple potential catalysts ahead

When a company is trading near reported cash levels with clinical catalysts in play… we pay attention. 👀

Paid Advertisement. Please see below.
https://t.co/hQOxetIBT5

[Momentum Source @MomentumSource]

🚨 $MDCX — THIS ONE HAS OUR ATTENTION 👀

Small-cap biotech. Multiple shots on goal. A valuation that’s hard to ignore.

🧬 FDA-authorized Phase 2b study
🎯 THREE clinical programs advancing
💰 ~$15M unrestricted cash reported
🔥 Market cap around just ~$16M
⏳ Multiple potential catalysts ahead

When a company is trading near reported cash levels with clinical catalysts in play… we pay attention. 👀

Paid Advertisement. Please see below.
https://t.co/hQOxetIBT5

[Momentum Source @MomentumSource]

🚨 NEW ALERT DROPPING TODAY at 8AM 🚨

We’ve been digging into a clinical-stage biotech sitting at a valuation that immediately caught our attention. 👀

🧬 FDA-authorized Phase 2b study
📊 THREE clinical programs advancing
💰 ~$15M in unrestricted cash reported
🎯 Multiple potential catalysts ahead
🔥 Valuation sitting around just ~$16M

Ticker reveal coming soon. ⏳

[Momentum Source @MomentumSource]

Traders are fearful based on recent data 👀

$SPY $QQQ $SPX

[Momentum Source @MomentumSource]

U.S. Treasury is forecasted to buy back $12.5 Billion of their own debt tomorrow

[Momentum Source @MomentumSource]

🚨 $SBFM FOLLOW-UP

THE MOVE IS UNDERWAY 👀

$SBFM just pushed to $1.31 after trading as low as $1.01 today — roughly a 30% intraday rebound with 7.7M+ shares traded.

And remember what hit this morning:

🧬 K1.1 mRNA showed in-vivo tumor suppression in at least TWO liver cancer mouse models
💉 Next step: pairing K1.1 mRNA with a cancer vaccine for NSCLC
💊 60 generic drugs already marketed in Canada
📈 ~12 additional launches planned for 2026 (Stock Titan)

With a market cap still around $5M, this is exactly why $SBFM was on our radar.

$1.31 is now the level I’m watching. 👀

Full breakdown: The Momentum Source — SBFM

Paid advertisement. See full disclosure on https://t.co/6Z0i4ArsaH

[Momentum Source @MomentumSource]

$SBFM Reports Preclinical Tumor Suppression with K1.1 mRNA in Liver Cancer; Advances mRNA-Cancer Vaccine for Difficult-to-Treat Lung Cancer

[Momentum Source @MomentumSource]

🚨 $SBFM — ONE TO WATCH

Sunshine Biopharma is sitting at an interesting valuation as its generic-drug platform continues to expand. 👀

• $9.26M Q2 revenue
• $13.75M cash reported at June 30
• 60 generic prescription drugs already on the Canadian market
• Amoxicillin now shipping to pharmacies
• Enalapril approved with shipments expected by year-end
• Rivaroxaban rollout targeted for October
• Market cap around just $4.5M at this morning’s snapshot

That means the reported June cash balance alone was roughly 3X the company’s recent equity value.
Now the chart is sitting in oversold territory with RSI near 29.5. The levels I’m watching: $1.17 → $1.20 → $1.25 for potential confirmation. 👀

With an operating pharmaceutical business + multiple product catalysts ahead, $SBFM is firmly on my radar.

Full breakdown 👇
The Momentum Source — SBFM Report
https://t.co/6Z0i4ArsaH